	US 12,012,456 B2
	Anti-interleukin-4 receptor (IL-4R) single-domain antibody, encoding polynucleotide and methods of making and using the antibody for IL-4R detection and disease treatment
Yakun Wan, Shanghai (CN); Min Zhu, Shanghai (CN); Junwei Gai, Shanghai (CN); and Xiaoning Shen, Shanghai (CN)
Assigned to SHANGHAI NOVAMAB BIOPHARMACEUTICALS CO., LTD., Shanghai (CN)
Appl. No. 17/772,350
Filed by SHANGHAI NOVAMAB BIOPHARMACEUTICALS CO., LTD., Shanghai (CN)
PCT Filed Jul. 31, 2020, PCT No. PCT/CN2020/106311 § 371(c)(1), (2) Date Apr. 27, 2022, PCT Pub. No. WO2021/082573, PCT Pub. Date May 6, 2021.
Claims priority of application No. 201911054787.9 (CN), filed on Oct. 31, 2019.
Prior Publication US 2022/0411519 A1, Dec. 29, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 47/68 (2017.01); C12N 15/85 (2006.01)

CPC C07K 16/2866 (2013.01) [A61K 47/6849 (2017.08); C12N 15/85 (2013.01); C07K 2317/24 (2013.01); C07K 2317/35 (2013.01); C07K 2317/569 (2013.01); C07K 2319/30 (2013.01); C12N 2800/107 (2013.01)]

21 Claims

1. An anti-IL-4R single-domain antibody, which has a VHH chain comprising framework regions (FRs) and complementarity determining regions (CDRs), wherein the CDRs comprise CDR1 as shown in SEQ ID NO: 1, CDR2 as shown in SEQ ID NO: 2, and CDR3 as shown in SEQ ID NO: 3.